Weighted Average Number of Shares Outstanding, Diluted of Enveric Biosciences, Inc. from 31 Mar 2014 to 30 Sep 2025

Taxonomy & unit
us-gaap: shares
Description
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
Summary
Enveric Biosciences, Inc. quarterly and annual Weighted Average Number of Shares Outstanding, Diluted in shares history and change rate from 31 Mar 2014 to 30 Sep 2025.
  • Enveric Biosciences, Inc. Weighted Average Number of Shares Outstanding, Diluted for the quarter ending 30 Sep 2025 was 313,242, a 548% increase year-over-year.
  • Enveric Biosciences, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2024 was 502,900, a 249% increase from 2023.
  • Enveric Biosciences, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2023 was 143,938, a 90% decline from 2022.
  • Enveric Biosciences, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2022 was 1,446,007.
Source SEC data
View on sec.gov
Weighted Average Number of Shares Outstanding, Diluted, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Quarterly Change (%)
Weighted Average Number of Shares Outstanding, Diluted, Annual (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Annual Change (%)

Enveric Biosciences, Inc. Quarterly Weighted Average Number of Shares Outstanding, Diluted (shares)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 313,242 +264,892 +548% 01 Jul 2025 30 Sep 2025 10-Q 14 Nov 2025 2025 Q3
Q2 2025 2,595,728 +2,089,871 +413% 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025 2025 Q2
Q1 2025 1,797,774 +1,531,010 +574% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q4 2024 502,900 +358,962 +249% 01 Oct 2024 31 Dec 2024 10-K 28 Mar 2025 2024 FY
Q3 2024 48,350 -2,116,306 -98% 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2025 2025 Q3
Q2 2024 505,857 -1,601,726 -76% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025 2025 Q2
Q1 2024 266,764 -1,811,507 -87% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025 2025 Q1
Q4 2023 143,938 01 Oct 2023 31 Dec 2023 10-K 28 Mar 2025 2024 FY
Q3 2023 2,164,656 +377,421 +21% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024 2024 Q3
Q2 2023 2,107,583 +1,053,823 +100% 01 Apr 2023 30 Jun 2023 10-Q 12 Aug 2024 2024 Q2
Q1 2023 2,078,271 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024 2024 Q1
Q3 2022 1,787,235 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023 2023 Q3
Q2 2022 1,053,760 01 Apr 2022 30 Jun 2022 10-Q 11 Aug 2023 2023 Q2
Q3 2020 5,289,099 +3,175,872 +150% 01 Jul 2020 30 Sep 2020 10-Q 16 Nov 2020 2020 Q3
Q2 2020 3,518,118 +1,491,023 +74% 01 Apr 2020 30 Jun 2020 10-Q 14 Aug 2020 2020 Q2
Q1 2020 3,175,040 +1,367,637 +76% 01 Jan 2020 31 Mar 2020 10-Q 15 May 2020 2020 Q1
Q4 2019 2,128,806 +1,177,205 +124% 01 Oct 2019 31 Dec 2019 10-K/A 12 Aug 2020 2019 FY
Q3 2019 2,113,227 -22,071,037 -91% 01 Jul 2019 30 Sep 2019 10-Q 16 Nov 2020 2020 Q3
Q2 2019 2,027,095 -16,763,903 -89% 01 Apr 2019 30 Jun 2019 10-Q 14 Aug 2020 2020 Q2
Q1 2019 1,807,403 -16,846,794 -90% 01 Jan 2019 31 Mar 2019 10-Q 15 May 2020 2020 Q1
Q4 2018 951,601 -14,031,190 -94% 01 Oct 2018 31 Dec 2018 10-K/A 12 Aug 2020 2019 FY
Q3 2018 24,184,264 +9,468,317 +64% 01 Jul 2018 30 Sep 2018 10-Q 08 Nov 2019 2019 Q3
Q2 2018 18,790,998 +4,180,389 +29% 01 Apr 2018 30 Jun 2018 10-Q 14 Aug 2019 2019 Q2
Q1 2018 18,654,197 +4,559,661 +32% 01 Jan 2018 31 Mar 2018 10-Q 14 May 2019 2019 Q1
Q4 2017 14,982,791 +1,914,194 +15% 01 Oct 2017 31 Dec 2017 10-K 26 Mar 2019 2018 FY
Q3 2017 14,715,947 +1,062,361 +7.8% 01 Jul 2017 30 Sep 2017 10-Q 14 Nov 2018 2018 Q3
Q2 2017 14,610,609 +1,765,552 +14% 01 Apr 2017 30 Jun 2017 10-Q 14 Aug 2018 2018 Q2
Q1 2017 14,094,536 +2,220,175 +19% 01 Jan 2017 31 Mar 2017 10-Q 15 May 2018 2018 Q1
Q4 2016 13,068,597 +1,967,399 +18% 01 Oct 2016 31 Dec 2016 10-K 02 Apr 2018 2017 FY
Q3 2016 13,653,586 +3,660,758 +37% 01 Jul 2016 30 Sep 2016 10-Q 13 Nov 2017 2017 Q3
Q2 2016 12,845,057 -4,449,563 -26% 01 Apr 2016 30 Jun 2016 10-Q 14 Aug 2017 2017 Q2
Q1 2016 11,874,361 +1,881,533 +19% 01 Jan 2016 31 Mar 2016 10-Q/A 15 May 2017 2017 Q1
Q4 2015 11,101,198 01 Oct 2015 31 Dec 2015 10-K/A 04 Apr 2017 2016 FY
Q3 2015 9,992,828 01 Jul 2015 30 Sep 2015 10-Q 14 Nov 2016 2016 Q3
Q2 2015 17,294,620 +7,301,792 +73% 01 Apr 2015 30 Jun 2015 10-Q 12 Aug 2016 2016 Q2
Q1 2015 9,992,828 01 Jan 2015 31 Mar 2015 10-Q 16 May 2016 2016 Q1
Q2 2014 9,992,828 01 Apr 2014 30 Jun 2014 10-Q 18 Aug 2015 2015 Q1

Enveric Biosciences, Inc. Annual Weighted Average Number of Shares Outstanding, Diluted (shares)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 502,900 +358,962 +249% 01 Jan 2024 31 Dec 2024 10-K 28 Mar 2025 2024 FY
2023 143,938 -1,302,069 -90% 01 Jan 2023 31 Dec 2023 10-K 28 Mar 2025 2024 FY
2022 1,446,007 01 Jan 2022 31 Dec 2022 10-K 26 Mar 2024 2023 FY
2019 2,128,806 +1,177,205 +124% 01 Jan 2019 31 Dec 2019 10-K/A 12 Aug 2020 2019 FY
2018 951,601 -14,031,190 -94% 01 Jan 2018 31 Dec 2018 10-K/A 12 Aug 2020 2019 FY
2017 14,982,791 +1,914,194 +15% 01 Jan 2017 31 Dec 2017 10-K 26 Mar 2019 2018 FY
2016 13,068,597 +1,967,399 +18% 01 Jan 2016 31 Dec 2016 10-K 02 Apr 2018 2017 FY
2015 11,101,198 +11,001,973 +11088% 01 Jan 2015 31 Dec 2015 10-K/A 04 Apr 2017 2016 FY
2014 99,225 +33,716 +51% 01 Apr 2014 31 Mar 2015 10-KT 15 Mar 2016 2015 T3
2013 65,509 01 Apr 2013 31 Mar 2014 10-KT 15 Mar 2016 2015 T3
* An asterisk sign (*) next to the value indicates that the value is likely invalid.